SCHEMBL647500

SCHEMBL647500

C[C@@H](CO)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.48
TSHR P16473 4/20 0.44
SLC1A3 P43003 2/20 0.44
SLC1A2 P43004 2/20 0.44
SLC1A1 P43005 2/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPT P10636 1/20 0.44
ALDH1A1 P00352 2/20 0.44
RCE1 Q9Y256 1/20 0.43
HTT P42858 3/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
IDO1 P14902 1/20 0.41
AGXT P21549 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL647501 1.00 TRPA1 (0.48) TRPA1TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL3813606 1.00 TRPA1 (0.48) TRPA1TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL2781956 0.93 MAPT (0.43) TRPA1TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL23423410 0.93 MAPT (0.43) TRPA1TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL872642 0.93 MAPT (0.43) TRPA1TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL27133457 0.89 TRPA1 (0.41) TRPA1TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL27032735 0.89 TRPA1 (0.41) TRPA1TSHRSLC1A3SLC1A2SLC1A1
SCHEMBL2304714 0.85 TSHR (0.48) TRPA1TSHRKMT2AMAPTALDH1A1
SCHEMBL17525899 0.85 TSHR (0.48) TRPA1TSHRKMT2AMAPTALDH1A1
SCHEMBL27902244 0.85 TRPA1 (0.50) TRPA1TSHRSLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144795-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS H. LUNDBECK A/S (DK) 2026-05-28 US disclosed
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-05-21 US disclosed
EP-4724440-A1 METHODS OF TREATING INFLAMMATORY DISEASES Interline Therapeutics, Inc. (US) 2026-04-15 EP disclosed
US-20260098039-A1 SOLID FORMS OF COMPOUND I OR SALTS THEREOF JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2026-04-09 US disclosed
EP-4652164-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2025-11-26 EP disclosed
EP-4611820-A1 EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOF ALX Oncology Inc. (US) 2025-09-10 EP disclosed
CN-120118087-A Preparation and application of PARP7 inhibitor 药雅科技(上海)有限公司 2025-06-10 CN disclosed
CN-119731176-A Solid forms of Compound I or salts thereof 北京加科思新药研发有限公司 2025-03-28 CN disclosed
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
WO-2024254539-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS, INC. (US) 2024-12-12 WO disclosed
US-4642373-A Substituted dodecahydrotripheylenes, and decahydropyrrolo[1,2-f]phenanthridines as CNS agents PFIZER INC. (US) 1987-02-10 US disclosed
EP-0090526-B1 SUBSTITUTED DODECAHYDROTRIPHENYLENES, DECAHYDRO-1H-CYCLOPENTA(1)PHENANTHRENES, DECAHYDRO-1H-PYRIDO(1,2-F)PHENANTHRIDINES AND DECAHYDROPYRROLO(1,2-F)PHENANTHRIDINES AS CNS AGENTS PFIZER INC. (US) 1986-11-26 EP disclosed
US-4576964-A ANALGESICS, ANTIEMETICS PFIZER INC. (US) 1986-03-18 US disclosed
EP-0079134-B1 STEREOSPECIFIC SYNTHESIS OF 5-PHENYL-2S-PENTANOL PFIZER INC. (US) 1985-02-06 EP disclosed
US-4476131-A ANTIEMETICS, ANALGESICS PFIZER INC. (US) 1984-10-09 US disclosed
US-4473704-A ANALGESICS, ANTIEMETICS PFIZER INC. (US) 1984-09-25 US disclosed
US-4412958-A Stereospecific synthesis of 5-phenyl-2S-pentanol PFIZER INC. (US) 1983-11-01 US disclosed
EP-0090526-A1 Substituted dodecahydrotriphenylenes, decahydro-1H-cyclopenta(1)phenanthrenes, decahydro-1H-pyrido(1,2-f)phenanthridines and decahydropyrrolo(1,2-f)phenanthridines as CNS agents PFIZER INC. (US) 1983-10-05 EP disclosed
EP-0090516-A1 Substituted hexahydropyrrolo(1,2-a)-quinoline, hexahydro-1H-pyrido(1,2-a)-quinoline, hexahydrobenzo(3)indene and octahydrophenanthrene CNS agents PFIZER INC. (US) 1983-10-05 EP disclosed
EP-0079134-A1 Stereospecific synthesis of 5-phenyl-2S-pentanol PFIZER INC. (US) 1983-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144795-A1 SPIROMACROCYCLIC OREXIN 2 RECEPTOR AGONISTS HCRTR2, HCRTR1, CRHR1 TRPA1 516/4885TSHR 119/4885SLC1A3 1051/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 TRPA1 4407/4885TSHR 3587/4885SLC1A3 4627/4885
US-20260137706-A1 METHODS OF TREATING INFLAMMATORY DISEASES NR3C1, CCR1, CXCR2 TRPA1 2630/4885TSHR 1291/4885SLC1A3 3048/4885
US-20260098039-A1 SOLID FORMS OF COMPOUND I OR SALTS THEREOF LDHA, SLC25A11, LDHB TRPA1 1405/4885TSHR 2751/4885SLC1A3 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.